Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Four retrospective studies were recently published on efficacy of aspirin in patients with
surgically resected colon cancer. Two of these studies strongly suggested that aspirin used
in low doses (100 mg/d) after surgical resection of colorectal cancer with PI3K mutation
could act as a targeted therapy with a major protective effect on the risk of recurrence. The
other two studies did not confirm the benefit of aspirin in this situation. These four
retrospective studies provide an insufficient level of evidence to demonstrate the benefit of
low-dose aspirin as adjuvant to surgery for colorectal cancer. Therefore, it is necessary as
recommended in the conclusion of these studies and meta-analyses to perform a randomised
prospective study to validate these data.